Trial Profile
Dose-response study of SM-13496 in patients with schizophrenia [late Phase 2 study]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jun 2016
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 14 Jun 2016 New trial record